Matt is a Venture Partner based in our San Francisco Bay Area office. He serves as Executive Chairman of Addition Therapeutics, an SR One portfolio company, and as a resource to management teams across the portfolio. Matt has more than 30 years of experience in the research, development, and commercialization of innovative therapeutics. In 2012 Matt co-founded Audentes Therapeutics and served as Chief Executive Officer from the company’s inception until its acquisition by Astellas Pharma Inc. in January 2020 for $3B. Previously Matt worked for Genzyme Corporation, BioMarin Pharmaceutical, Amicus Therapeutics, and Iris Medicine. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed.
Matt is Chairman of the Board of Directors at Vor Biopharma, Inc. and Remix Therapeutics, Inc. He also served as a member of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector, from 2015-2021, and was Chairman in 2019 and 2020. Matt received his Bachelor’s degree in Biochemistry from Bowdoin College.